We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Nanometrics Inc | NASDAQ:NANO | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 35.33 | 34.00 | 35.30 | 0 | 01:00:00 |
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its half year results for the six months ended 30 June 2017.
Financial highlights
Financial events
Operational highlights
Financial Review (IFRS)
The detailed Profit & Loss financial statement is laid out below: 6 months period closed on : (€ ‘000) June 30 2017 June 30 2016 Operating revenue 59 982 Other revenue 1,823 2,053 Subsidies 63 63 Research Tax Credit 1,760 1,991 Total revenue 1,882 3,036 Cost of sales - - R&D costs -7,238 -8,209 Selling, general and administrative costs (SG&A) -4,531 -3,773 Costs associated with payments in shares -1,919 -1,127 Core operating loss -11,806 -10,073 Income from cash 19 35 Gross cost of debt -57 -49 Net cost of debt -38 -14 Other financial income 18 15 Other financial expenses -364 -6 Core pre-tax loss -12,190 -10,079 Income tax 0 -89 Net loss -12,190 -10,169 Actuarial gains 8 21 Foreign exchange translation adjustments 237 4 Comprehensive loss -11,945 -10,143 Diluted earnings per share -0.76 -0.68Total revenue for H1 2017 amounts to €1,882k (H1 2016: €3,036k):
Total operating expenses as of 30 June 2017 reached €13.7m (H1 2016: €13.1m). In total, the stability of expenses is explained as follows:
The core operating loss amounts to €11.8m (H1 2016: €10.1m) in line with expectations. This operating loss increase is mainly due to the decrease of revenue level.
The total net loss amounts to €12.2m.
Cash balance as of 30 June 2017 reaches €31m as per expectations.
The half year financial report has been the object of a limited review by the Statutory Auditors. The company published full financial statements that comply with IFRS that are available on its website at www.nanobiotix.com.
●●●
Next financial press release: revenue for the third quarter of 2017 on November 15, 2017.
●●●
About NANOBIOTIX: www.nanobiotix.com
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the treatment of cancer. The Company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to provide a new, more efficient treatment for cancer patients.
NanoXray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of solid tumors including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, etc., via multiple routes of administration.
NBTXR3 is being evaluated in: soft tissue sarcoma (STS), head and neck cancers, prostate cancer, and liver cancers (primary and metastases). Additionally, head and neck cancer and rectal cancer trials led by Nanobiotix’s Taiwanese partner, PharmaEngine, are underway in the Asia Pacific region. The Company has filed in August 2016 for market approval (CE Marking) in Europe for its lead product NBTXR3.
The Company started in 2016 a new preclinical research program in Immuno-oncology with its lead product NBTXR3, which could have the potential to bring a new dimension to cancer immunotherapies.
Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP). The Company Headquarter is based in Paris, France. Affiliate in Cambridge, United States.
Disclaimer
This press release contains certain forward-looking statements concerning Nanobiotix and its business. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of Nanobiotix filed with the French Financial Markets Authority (Autorité des Marchés Financiers) under number D.17-0470 on April 28, 2017 (a copy of which is available on www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.
This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Nanobiotix shares in any country. At the moment NBTXR3 does not bear a CE mark and is not permitted to be placed on the market or put into service until NBTXR3 has obtained a CE mark.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170831006107/en/
NanobiotixSarah Gaubert, +33 (0)1 40 26 07 55Director, Communications & Public Affairssarah.gaubert@nanobiotix.com / contact@nanobiotix.comorNoël Kurdi, +1-646-241-4400Director, Investor Relationsnoel.kurdi@nanobiotix.com / investors@nanobiotix.comorMedia relationsFrance - Springbok ConsultantsMarina Rosoff, +33 (0)6 71 58 00 34marina@springbok.frorUnited States – RooneyPartnersMarion Janic, +1-212-223-4017mjanic@rooneyco.com
1 Year Nanometrics Chart |
1 Month Nanometrics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions